A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes.
Ping ZhaoMeng-Meng JiYing FangXiao LiHong-Mei YiZi-Xun YanShu ChengPeng-Peng XuAnne JaninChao-Fu WangLi WangWei Li ZhaoPublished in: Cell death & disease (2021)
Long noncoding RNAs (lncRNAs) play an essential role in tumor progression. Few researches focused on the clinical and biological relevance of lncRNAs in peripheral T cell lymphoma (PTCL). In this research, a novel lncRNA (ENST00000503502) was identified overexpressed in the main subtypes of PTCL, and designated as T cell lymphoma-associated lncRNA1 (TCLlnc1). Serum TCLlnc1 was associated with extranodal involvement, high-risk International Prognostic Index, and poor prognosis of the patients. Both in vitro and in vivo, overexpression of TCLlnc1 promoted T-lymphoma cell proliferation and migration, both of which were counteracted by the knockdown of TCLlnc1 using small interfering RNAs. As the mechanism of action, TCLlnc1 directly interacted with transcription activator heterogeneous nuclear ribonucleoprotein D (HNRNPD) and Y-box binding protein-1 (YBX1) by acting as a modular scaffold. TCLlnc1/HNRNPD/YBX1 complex upregulated transcription of TGFB2 and TGFBR1 genes, activated the tumor growth factor-β signaling pathway, resulting in lymphoma progression, and might be a potential target in PTCL.
Keyphrases
- poor prognosis
- long non coding rna
- growth factor
- transcription factor
- binding protein
- end stage renal disease
- signaling pathway
- genome wide identification
- diffuse large b cell lymphoma
- newly diagnosed
- long noncoding rna
- chronic kidney disease
- peritoneal dialysis
- genome wide analysis
- pi k akt
- genome wide
- epithelial mesenchymal transition
- tissue engineering
- cell therapy
- mesenchymal stem cells
- oxidative stress
- bone marrow